TransMedics Group’s (TMDX) “Overweight” Rating Reiterated at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of TransMedics Group (NASDAQ:TMDX – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $145.00 price objective on the stock, up from their previous price objective of $125.00. A number of other research firms also recently weighed in on TMDX. […]
Piper Sandler reaffirmed their overweight rating on shares of TransMedics Group (NASDAQ:TMDX – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $145.00 price objective on the stock, up from their previous price objective of $125.00. A number of other research firms also recently weighed in on TMDX. […]
